Clinical Trial Update: Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ecteinascidin-743 (trabectedin) in patients with previously treated metastatic osteosarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Trabectedin (trabectedin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma | Phase 2 | Status: COMPLETED